Search Studies
Research studies are looking for volunteers just like you. Both healthy volunteers and participants with specific health conditions are needed to help answer important questions impacting the health of our friends and family. Join us to improve the health of others.
-
Ketogenic Diet Intervention to Improve Response to Immunotherapy: KetoIO
Official Title Phase I Study of the Safety and Feasibility of a Ketogenic Dietary Intervention to Improve Response to ImmunotherapyPurpose
This study will look at if a ketogenic diet (KD) can help treatment work better in patients with metastatic melanoma or metastatic kidney cancer. People who take part in the study will be randomly assigned to either continue eating their usual diet or trying the KD diet for 24 weeks. Participants will have blood and stool samples collected during the study. They will also test their sugar by doing daily glucose fingers sticks. Participants may be paid up to $200 for taking part in the study.
Could this study be right for you?
- Patients with metastatic melanoma receiving first-line treatment with immunotherapy or Patients with metastatic renal cell cancer receiving first line treatment with immunotherapy.
- Willing to give three stool samples
- Willing to participate in a ketogenic diet (KD)
Age Range
18 years and up -
The Perceptions of Gen Zs Regarding the Dietary Guidelines for Americans (DGA)
Official Title The Knowledge and Perceptions of Gen Zs Regarding the Dietary Guidelines for AmericansPurpose
- Use ideas from Social Cognitive Theory to describe Gen Zs regarding the Dietary Guidelines for Americans (DGA) 2020 to 2025
- Explain what Gen Z knows and believes regarding the MyPlate recommendations for healthy eating related to:
- Filling half their plate with fruit and vegetables
- Filling one-quarter of their plate with lean protein, and varying the sources of protein
- Filling one-quarter of their plate with grains, making half of the grains whole grains
- To describe the associations between demographic variables (ethnicity, education, household income, and home environment) and Gen Zs perceptions and knowledge of the DGA
Could this study be right for you?
18 to 28 years old
Live in the US
English speaker
Have access to a device that supports Zoom
Age Range
18 - 28 years -
Smartphone-based HIV-specific Smoking Cessation Study
Official Title AMC-111 Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility StudyPurpose
This clinical trial evaluates the usefulness of using a smartphone-based HIV-specific smoking cessation intervention at the time of lung cancer screening in helping people living with HIV quit smoking. Positively Smoke Free - Mobile may help patients with HIV quit smoking.
In this study, you will have lung cancer screening performed via a CT scan. You will also be enrolled into a self-guided smartphone-based HIV-specific smoking cessation intervention called “Positively Smoke Free - Mobile” lasting 42 days. After starting the intervention, you will be evaluated at 3, 6, and 12 months.
Could this study be right for you?
Must have at least a 20 pack-year history of smoking (a way to measure how much a person has smoked over time, 1 pack-year is a pack per day for a year or 2 packs of cigarettes for half a year, etc.)
Must have not had a CT scan in the past 12 months
HIV positive, and must be receiving antiretroviral therapy and have a CD4 count of at least 200cells/uL within 6 months of enrolling in the study
Able to understand and provide informed consent
Possess a smart phone that can browse the web
Not receiving any other smoking cessation interventions currently or within the prior 30 days
Female volunteers cannot be pregnant, lactating, or breast-feeding
Age Range
45 - 80 years -
A Study to Evaluate Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa
Official Title A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis suppurativaPurpose
This study is being done to see how well remibrutinib works for people who have hidradenitis suppurativa
Could this study be right for you?
- Subject must have a diagnosis of moderate to severe hidradenitis suppurativa (HS) for at least 6 months with lesions in 2 distinct areas
- Subject must be in good general health with no history of tuberculosis, HIV, or hepatitis B or C
- Subject must have no recent history (within 6 months) of significant medical conditions such as a heart attack or stroke
- Subject must not be taking anticoagulant medication (ex. warfarin) or dual anti-platelet therapy (ex. acetylsalicylic acid + clopidogrel)
Age Range
18 years and up -
A Long-term, observational study on the safety of TZIELD for patients with Stage 2, Type 1 Diabetes
Official Title AN OBSERVATIONAL, LONG-TERM SAFETY STUDY OF TZIELD® (TEPLIZUMAB-MZWV) IN PATIENTS WITH STAGE 2 TYPE 1 DIABETESPurpose
The objective of the study is to test the safety and efficacy of TZIELD over the course of 10 years in patients with Stage 2, Type 1 Diabetes, as well as the prevention of Stage 3, Type 1 Diabetes.
Could this study be right for you?
Inclusion Criteria:
TZIELD-Exposed Cohort
1. Patients in the US diagnosed with Stage 2 T1D who are planned to initiate TZIELD treatment according to the currently approved label or who have initiated TZIELD treatment within 6 months prior to enrollment:
− Day 1: 65 μg/m²
− Day 2: 125 μg/m²
− Day 3: 250 μg/m²
− Day 4: 500 μg/m²
− Days 5 through 14: 1,030 μg/m² per day
− Cumulative dose is approximately 11,240 μg/m²2. Appropriate written informed consent/assent as applicable for the age of the patient
TZIELD-Unexposed Cohort
1. Patients in the US diagnosed with Stage 2 T1D but who are not treated with TZIELD
2. Appropriate written informed consent/assent as applicable for the age of the patient
Exclusion Criteria:
1. Patients who initiated TZIELD treatment more than 6 months prior to enrollment
2. Patients who had participated in a previous clinical trial for TZIELD
3. Patients in an ongoing clinical trial of an investigational product or who had ended participation within 6 months prior to study enrollment; patients participating in other observational studies may be enrolled.Age Range
18 - 70 years -
Research Study on the Biomechanics of Total Knee Replacements
Official Title Biomechanical Metrics of Movement Relative to Total Knee ArthroplastyPurpose
This study aims to understand how a total knee replacement surgery (TKR) affects muscle function and movement in the lower body. It focuses on four key areas:
-
Examining how TKR changes the way muscles work in the lower body.
-
Exploring how these muscle changes relate to the forces people experience when walking and doing daily activities after surgery.
-
Connecting muscle function to how well patients feel and move after TKR.
-
Identifying different types of TKR patients based on their physical traits, movement patterns, and medical history to see how they compare.
Could this study be right for you?
- Must be scheduled to receive a total knee replacement within the next 2 months
- Have a body mass index (BMI) < 40
- Do not require the use of a cane or other assistive device when walking, climbing stairs, and getting up from a chair
Exclusion criteria varies; please contact Study Coordinator for more information
Age Range
18 years and up -
-
Impacts of Ketone Esters on Exercise and Heart Health in Type 2 Diabetics
Official Title Effects of Acute and Chronic Ketone Ester Consumption on Exercise Tolerance and Cardiac Function in Subjects with DiabetesPurpose
This placebo-controlled study is being done to evaluate the effects of a ketone ester drink on exercise performance and heart health in a group of subjects diagnosed with type 2 diabetes.
Could this study be right for you?
There are additional exclusion criteria, study staff will screen fully before enrollment.
Age Range
18 - 80 years -
Effect of Diet and Electrical Stimulation Exercise on Blood Pressure Control in Spinal Cord Injury
Official Title Lifestyle solutions to postprandial hypotension in spinal cord injuryPurpose
To test if a low-glycemic diet and electrical stimulation of leg muscles can improve blood pressure control after eating.
Could this study be right for you?
- Spinal cord injury sustained at least 1-year ago
- Level of injury between C4 and T10
- Use of wheelchair for majority of daily activities
Age Range
18 years and up -
Does the amount of nicotine in filtered little cigars impact health and smoking habits?
Official Title LOWFLC Study: Addiction potential of low nicotine filtered little cigarsPurpose
Researchers from The Ohio State University are recruiting adult users of little cigars and cigarillos to help improve understanding of the products’ health impact.
Could this study be right for you?
- Current smoker
- No significant health problems
Age Range
21 - 75 years -
A Study for Reducing Alcohol Use During MOUD (Phase Two)
Official Title Brief Digitally Enhanced Intervention for Managing Emotional Pain and Reducing Alcohol Use during Medication for OUD (Phase Two)Purpose
This study is being done to further examine and improve how a brief clinical treatment intervention may reduce alcohol use among patients engaged in medication for opioid use disorder (MOUD) treatment.
The length of the study is approximately 10 weeks and will include two on-campus lab visits at Ohio State's Medical Campus, daily surveys via a smartphone app (surveys 3 times a day for ~21 days), three treatment sessions (completed online or in-person), and follow-up questionnaires (completed online). The total time commitment of the study is 11 hours and 6 minutes.
Could this study be right for you?
Inclusion Criteria:
- engaged in MOUD treatment (for at least one month)
- alcohol consumption (within the past 12 months)
- age 18 or older
- access to a smart phone
(partial list of inclusion criteria)
Exclusion Criteria:
- diagnosis of psychosis or bipolar I
- currently pregnant (positive pregnancy test)
(partial list of exclusion criteria)
Age Range
18 years and up -
A Depression Study Examining the Effects of Lumateperone in Treatment-Resistant Depression
Official Title A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the
Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of
Patients with Major Depressive DisorderPurpose
Depression is one of the most common mental health issues worldwide. Many people with major depressive disorder (MDD) take antidepressant medications that do not provide enough of a response to ease their depressive symptoms.
The primary objective of this study is to evaluate the benefit of Lumateperone 42 mg administered once daily compared with placebo as adjunctive treatment to antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD) who have an inadequate response to ongoing ADT.
Could this study be right for you?
You may be able to take part if you:
• are 18–65 years of age
• have a confirmed diagnosis of Major Depressive Disorder (MDD)
• feel that your current antidepressant medication is not working well
• Has tried 2 or more antidepressant medication in the current episode of depression
Other criteria will need to be met to confirm your eligibility for this study.
Age Range
18 - 65 years -
A First-in-human Study of a New Gene Therapy (AMT-260) in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE)
Official Title A Multi-center, Phase 1/2a, First-in-human (FIH) Study Investigating the Safety, Tolerability, and Efficacy of AMT-260 in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE) Administered via Magnetic Resonance Imaging (MRI)-guided Convection-enhanced Delivery (CED)Purpose
You are being invited to participate in a study about mesial temporal lobe epilepsy (MTLE) on only 1 side (unilateral) of the brain that has not responded to medication (refractory).
The study will test AMT-260, which is a new gene therapy under investigation for use in treating people like you with MTLE. It is not yet approved as a drug for treating MTLE. It can only be used in a study like this one. This is the first time this gene therapy will be used in humans. It has previously been studied in animals.
AMT-260 is a gene therapy designed to reduce the electrical signals between nerve cells (neurons) in the parts of your brain where nerve cells are abnormally connected. This reduces the extra electrical signals that happen at the same time and is intended to reduce your seizure activity.
The overall goals of this study are:
- To observe whether participants have any side effects from AMT-260 or from the procedure to deliver AMT-260 into the brain and how well participants tolerate any side effects that may occur.
- To measure if participants have changes in:
- frequency of their seizures
- how their seizures affect their life
- how the human body takes up and removes AMT-260
- To find the best dose of AMT-260 for future participants to ensure clinical benefit with minimal or no side effects.
Could this study be right for you?
Adult, 18-65 years of age, inclusive, capable of giving informed consent.
Written informed consent is given freely after the nature of the study has been explained to the participant and the completion of data disclosure.
Willingness to undergo necessary surgical procedures.
Diagnosis of unilateral refractory MTLE for ≥360 days, confirmed by an Epilepsy Monitoring Unit.Additional Eligibility Criteria to be assessed by neurosurgery team, and as described in the study protocol.
Age Range
18 - 65 years